FOLD - Amicus Therapeutics, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
15.90
-0.25 (-1.55%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close16.15
Open16.06
Bid10.15 x 100
Ask15.90 x 2000
Day's Range15.70 - 16.30
52 Week Range5.07 - 16.60
Volume2,812,831
Avg. Volume2,307,398
Market Cap2.644B
Beta1.16
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Amicus Therapeutics (FOLD) Surges: Stock Moves 9.2% Higher
    Zacks11 days ago

    Amicus Therapeutics (FOLD) Surges: Stock Moves 9.2% Higher

    Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

  • January Growth Opportunities – Athenex And More
    Simply Wall St.21 days ago

    January Growth Opportunities – Athenex And More

    Why invest in a stock whose growth outlook that lags behind the market? Investors looking for companies with extraordinary future prospects in terms of profitability and returns should look atRead More...

  • Investopedia24 days ago

    3 Small Biotechs With Big Upside

    Biotech stocks have broken out and in some cases could be set to rise sharply over the next few months.

  • Capital Cube24 days ago

    ETFs with exposure to Amicus Therapeutics, Inc. : December 28, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Amicus Therapeutics, Inc. Here are 5 ETFs with the largest exposure to FOLD-US. Comparing the performance and risk of Amicus Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • This Tiny Biotech Pins Hope on U.S. Approval
    Motley Foollast month

    This Tiny Biotech Pins Hope on U.S. Approval

    A new treatment of Fabry disease could be available in the United States as soon as 2018.

  • Capital Cube2 months ago

    ETFs with exposure to Amicus Therapeutics, Inc. : December 5, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Amicus Therapeutics, Inc. Here are 5 ETFs with the largest exposure to FOLD-US. Comparing the performance and risk of Amicus Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Amicus Therapeutics, Inc. :FOLD-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017
    Capital Cube2 months ago

    Amicus Therapeutics, Inc. :FOLD-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017

    Categories: Yahoo FinanceGet free summary analysis Amicus Therapeutics, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Amicus Therapeutics, Inc. – Protalix Biotherapeutics, Inc., Biogen Inc., BioMarin Pharmaceutical Inc., Esperion Therapeutics, Inc., GlaxoSmithKline plc Sponsored ADR, Shire PLC Sponsored ADR, Novo Nordisk A/S Sponsored ADR ... Read more (Read more...)

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of FOLD earnings conference call or presentation 8-Nov-17 1:30pm GMT

    Q3 2017 Amicus Therapeutics Inc Earnings Call

  • November Top Growth Companies
    Simply Wall St.2 months ago

    November Top Growth Companies

    Individual investors like stocks with a high growth potential. These companies have a strong outlook that can bring a significant upside to your portfolio, regardless of market cyclicality. Analysing theRead More...

  • Is It Time To Buy Amicus Therapeutics Inc (FOLD)?
    Simply Wall St.2 months ago

    Is It Time To Buy Amicus Therapeutics Inc (FOLD)?

    Amicus Therapeutics Inc (NASDAQ:FOLD), a biotechnology company based in United States, saw a decent share price growth in the teens level on the NasdaqGM over the last few months. WithRead More...

  • Associated Press2 months ago

    Amicus Therapeutics reports 3Q loss

    On a per-share basis, the Cranbury, New Jersey-based company said it had a loss of 69 cents. Losses, adjusted for one-time gains and costs, came to 41 cents per share. The results missed Wall Street expectations. ...

  • Capital Cube2 months ago

    Amicus Therapeutics, Inc. – Value Analysis (NASDAQ:FOLD) : November 7, 2017

    Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Amicus Therapeutics, Inc. a score of 19. Our analysis is based on comparing Amicus Therapeutics, Inc. with the following peers – Protalix Biotherapeutics, Inc., Biogen Inc., BioMarin Pharmaceutical Inc., Esperion Therapeutics, Inc., GlaxoSmithKline plc Sponsored ADR, Shire PLC Sponsored ADR, Novo Nordisk A/S Sponsored ADR Class B ... Read more (Read more...)

  • Should You Sell Amicus Therapeutics, Inc. (FOLD) Before Earnings?
    Zacks2 months ago

    Should You Sell Amicus Therapeutics, Inc. (FOLD) Before Earnings?

    Amicus Therapeutics, Inc. (FOLD) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

  • Amicus Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : FOLD-US : November 6, 2017
    Capital Cube3 months ago

    Amicus Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : FOLD-US : November 6, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Amicus Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)

  • These Biotech Stocks Are Pricey, but Investors Can Still Buy Them
    Motley Fool3 months ago

    These Biotech Stocks Are Pricey, but Investors Can Still Buy Them

    Sarepta Therapeutics and Amicus Therapeutics are tackling the unmet need for new treatments for rare conditions, and that could put them in position to generate market-beating returns.

  • Amicus Therapeutics (FOLD) Soars: Stock Adds 9.2% in Session
    Zacks4 months ago

    Amicus Therapeutics (FOLD) Soars: Stock Adds 9.2% in Session

    Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

  • Why These Biotechs Are Leading The Group Near A 21-Month High
    Investor's Business Daily4 months ago

    Why These Biotechs Are Leading The Group Near A 21-Month High

    Biotech stocks narrowed in on a 21-month high Wednesday with big rises coming from the likes of Intercept, Amicus and Exelixis on positive drug and partnership news.

  • Evidence of Biotech Froth Continues to Mount
    Bloomberg4 months ago

    Evidence of Biotech Froth Continues to Mount

    Investors keep driving up shares based on shaky trial data.

  • Benzinga4 months ago

    There's Good Cause To Be Excited About Amicus Therapeutics Clinical Program

    Shares of Amicus Therapeutics, Inc. (NASDAQ: FOLD ) were trading higher by more than 12 percent Wednesday after the company released encouraging clinical trial data. The company's therapy showed a greater ...

  • GuruFocus.com4 months ago

    Weekly CEO Buys Highlights

    Insiders invest in RH and Amicus Therapeutics

  • Reuters4 months ago

    Amicus abandons wound treatment, focus shifts to future trial data

    Amicus Therapeutics Inc said on Wednesday it would stop developing its experimental drug for healing wounds related to a rare skin disease, but shares of the company rose as investors appeared to focus on the drug developer's expanding pipeline. Amicus's shares rose as much as 6 percent in morning trading, recovering from a nearly 15 percent slide before the bell.

  • Lincoln National, Sears, Hasbro, Steris & Amicus Therapeu...
    CNBC Videos11 days ago

    Lincoln National, Sears, Hasbro, Steris & Amicus Therapeu...

    The "Halftime Report" traders give their top stocks to watch for the second half.